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Background
Fc-mediated inhibitory activity of neutralizing antibodies
has been shown to participate in HIV protection (Hessell
et al. 2007). In addition, a non-neutralizing antibody
F240 was found to partially protect macaques from SHIV
vaginal transmission (Moore et al., 2011). However,
mechanisms involved in this protection need further
investigations. In this study, two non-neutralizing antibo-
dies have been selected on the basis of their Fc-mediated
inhibitory functions in vitro for further analysis of their
protective role on vaginal challenge in non-human
primate (NHP).
Methods
We have assessed and scored various in vitro HIV-
inhibitory activities of non-neutralizing antibodies:
Fc-mediated inhibition of macrophages through phago-
cytosis of immunecomplexes, ADCC in primary infected
CD4+ T lymphocytes by autologous NK cells, capture of
native primary virus particles. Efficacy of two anti-PID
antibodies with high in vitro functional scores has been
tested in NHP. The combination of two antibodies for-
mulated in 1.6% HEC gel has been topically applied in
the vagina of macaques (n=6), 1 hour before vaginal
challenge with high dose (10 AID50) of SHIVSF162P3.
Infection was followed by assessing viral load in the
plasma.
Results
Although unable to block virus entry at mucosal site as
all treated animals became persistently infected, the
antibody treated macaques have significant decrease of
plasma viral load (day 7, p=0.0479; day 14, p=0.0351,
day 42: p=0.0370).
Conclusion
Decrease in viral load following antibody treatment
strongly suggests that non-neutralizing inhibitory anti-
bodies could interfere with early viral replication and
dissemination through Fc-mediated inhibitory functions.
Additional studies will be required to optimize this inhi-
bition, and combined strategies should be developed to
assess the potential synergy between neutralizing and
non-neutralizing inhibitory antibodies.
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